Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

Circulation: Cardiovascular Interventions: The First 10 Years.

Faxon DP, Leopold JA, Abbott JD, McElhinney DB, Williams DO.

Circ Cardiovasc Interv. 2018 Jun;11(6):e006901. doi: 10.1161/CIRCINTERVENTIONS.118.006901. No abstract available.

PMID:
29895606
2.

Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease.

Bravo CA, Hirji SA, Bhatt DL, Gluud C, Faxon DP, Ohman EM, Kaneko T, Engstrøm T, Høfsten DE, Brennan JM.

Heart. 2018 Jul;104(14):1144-1147. doi: 10.1136/heartjnl-2017-312857. Epub 2018 Feb 8. No abstract available.

PMID:
29439169
3.

Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock.

Vaduganathan M, Qamar A, Badreldin HA, Faxon DP, Bhatt DL.

JACC Cardiovasc Interv. 2017 Dec 11;10(23):2468-2469. doi: 10.1016/j.jcin.2017.10.003. No abstract available.

PMID:
29217013
4.

Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

Bossard M, Granger CB, Tanguay JF, Montalescot G, Faxon DP, Jolly SS, Widimsky P, Niemela K, Steg PG, Natarajan MK, Gao P, Fox KAA, Yusuf S, Mehta SR.

J Am Heart Assoc. 2017 Nov 3;6(11). pii: e006577. doi: 10.1161/JAHA.117.006577.

5.

Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience.

Vaduganathan M, Qamar A, Badreldin HA, Faxon DP, Bhatt DL.

JACC Cardiovasc Interv. 2017 Aug 28;10(16):1712-1714. doi: 10.1016/j.jcin.2017.07.009. No abstract available.

PMID:
28838482
6.

Balanced Adoption of Radial Artery Access for Primary Percutaneous Coronary Intervention.

Anderson HV, Faxon DP.

JAMA Cardiol. 2017 Oct 1;2(10):1059-1060. doi: 10.1001/jamacardio.2017.2346. No abstract available.

PMID:
28813571
7.

Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis.

Mangione FM, Jatene T, Badr Eslam R, Bergmark BA, Gallagher JR, Shah PB, Mauri L, Leopold JA, Sobieszczyk PS, Faxon DP, Croce KJ, Bhatt DL, Devlin PM.

Am J Cardiol. 2017 Aug 1;120(3):369-373. doi: 10.1016/j.amjcard.2017.04.036. Epub 2017 May 10.

PMID:
28583681
8.

Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease.

Bravo CA, Hirji SA, Bhatt DL, Kataria R, Faxon DP, Ohman EM, Anderson KL, Sidi AI, Sketch MH Jr, Zarich SW, Osho AA, Gluud C, Kelbæk H, Engstrøm T, Høfsten DE, Brennan JM.

Cochrane Database Syst Rev. 2017 May 3;5:CD011986. doi: 10.1002/14651858.CD011986.pub2. Review.

PMID:
28470696
9.

Establishing A Contemporary Training Curriculum for the Next Generation of Interventional Cardiology Fellows.

Golwala HB, Kalra A, Faxon DP.

Circ Cardiovasc Interv. 2017 Apr;10(4). pii: e005273. doi: 10.1161/CIRCINTERVENTIONS.117.005273. No abstract available.

10.

Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital.

Vaduganathan M, Qamar A, Singh A, Venkateswaran RV, Szumita PM, Croce KJ, Mauri L, Leopold JA, Shah PB, Sobieszczyk P, Faxon DP, Bhatt DL.

J Am Coll Cardiol. 2017 Jan 31;69(4):463-464. doi: 10.1016/j.jacc.2016.11.017. Epub 2016 Nov 30. No abstract available.

11.

Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.

Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S.

Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1176-1184. doi: 10.1002/ccd.26831. Epub 2016 Nov 10.

12.

Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004395. Review.

13.

The BIOSOLVE II trial: a step forward for the bioresorbable scaffold?

Faxon DP.

Eur Heart J. 2016 Sep 14;37(35):2710-2. doi: 10.1093/eurheartj/ehw227. Epub 2016 Jun 26. No abstract available.

PMID:
27354050
14.

Interventional Cardiology: Current Status and Future Directions in Coronary Disease and Valvular Heart Disease.

Faxon DP, Williams DO.

Circulation. 2016 Jun 21;133(25):2697-711. doi: 10.1161/CIRCULATIONAHA.116.023551. Review. No abstract available.

15.

Cardiovascular Registries: Too Much of Good Thing?

Faxon DP, Burgess A.

Circ Cardiovasc Interv. 2016 Apr;9(4):e003866. doi: 10.1161/CIRCINTERVENTIONS.116.003866. No abstract available.

16.

Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.

Thukkani AK, Agrawal K, Prince L, Smoot KJ, Dufour AB, Cho K, Gagnon DR, Sokolovskaya G, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S.

J Am Coll Cardiol. 2015 Sep 8;66(10):1091-101. doi: 10.1016/j.jacc.2015.06.1339.

17.

Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.

Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S.

Heart. 2015 Oct;101(19):1569-76. doi: 10.1136/heartjnl-2014-307168. Epub 2015 Jul 24.

18.

Coronary venous interventions: failed strategy or inadequately explored?

Faxon DP.

Circ Cardiovasc Interv. 2015 May;8(5). pii: e002743. doi: 10.1161/CIRCINTERVENTIONS.115.002743. No abstract available.

19.

Can BRIGHT restore the glow of bivalirudin?

Cavender MA, Faxon DP.

JAMA. 2015 Apr 7;313(13):1323-4. doi: 10.1001/jama.2015.2345. No abstract available.

PMID:
25774963
20.

The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.

Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY.

Thromb Haemost. 2014 Dec;112(6):1080-7. doi: 10.1160/TH14-08-0681. Epub 2014 Oct 9. Review.

PMID:
25298351
21.

Variability in the use of invasive services: sign of poor quality of care or an opportunity to improve care?

Faxon DP.

Circ Cardiovasc Interv. 2014 Apr;7(2):133-5. doi: 10.1161/CIRCINTERVENTIONS.114.001477. No abstract available.

22.

The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study.

Bainey KR, Gafni A, Rao-Melacini P, Tong W, Steg PG, Faxon DP, Lamy A, Granger CB, Yusuf S, Mehta SR; TIMACS Investigators.

J Med Econ. 2014 Jun;17(6):415-22. doi: 10.3111/13696998.2014.911184. Epub 2014 Apr 16.

PMID:
24702256
23.

ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 performance measures for adults undergoing percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance.

Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B.

J Am Coll Cardiol. 2014 Feb 25;63(7):722-745. doi: 10.1016/j.jacc.2013.12.003. Epub 2013 Dec 19. No abstract available.

24.

ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance.

Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B.

Circulation. 2014 Feb 25;129(8):926-49. doi: 10.1161/01.cir.0000441966.31451.3f. Epub 2013 Dec 19. No abstract available.

25.

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.

BMJ. 2013 Nov 8;347:f6625. doi: 10.1136/bmj.f6625.

26.

A new series: Clinical Dilemmas in Interventional Cardiology.

Faxon DP, Rihal C.

Circ Cardiovasc Interv. 2013 Oct 1;6(5):493. doi: 10.1161/CIRCINTERVENTIONS.113.000859. No abstract available.

27.

The great taboo of non-infarct-related artery revascularization during primary percutaneous coronary intervention.

Bangalore S, Faxon DP.

Am Heart J. 2013 Oct;166(4):611-3. doi: 10.1016/j.ahj.2013.06.026. Epub 2013 Sep 14. No abstract available.

PMID:
24093838
28.

Changes in medical publishing: the challenges for an interventional journal.

Faxon DP.

Circ Cardiovasc Interv. 2013 Feb;6(1):2-4. doi: 10.1161/CIRCINTERVENTIONS.112.000174. No abstract available.

29.

Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.

Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group.

J Am Coll Cardiol. 2013 Feb 19;61(7):702-11. doi: 10.1016/j.jacc.2012.11.036.

30.

How to manage antiplatelet therapy for stenting in a patient requiring oral anticoagulants.

Faxon DP.

Curr Treat Options Cardiovasc Med. 2013 Feb;15(1):11-20. doi: 10.1007/s11936-012-0222-5.

PMID:
23180387
31.

Very late stent thrombosis: current concepts.

Siddiqi OK, Faxon DP.

Curr Opin Cardiol. 2012 Nov;27(6):634-41. doi: 10.1097/HCO.0b013e3283587c7e. Review.

PMID:
23075822
32.

Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease.

Gössl M, Faxon DP, Bell MR, Holmes DR, Gersh BJ.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):597-604. doi: 10.1161/CIRCINTERVENTIONS.111.965509. Review. No abstract available.

33.

The changing face of interventional cardiology.

Faxon DP, Williams DO.

Circ Cardiovasc Interv. 2012 Jun;5(3):325-7. doi: 10.1161/CIRCINTERVENTIONS.112.971671. No abstract available.

34.

Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.

Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.

Circ Cardiovasc Interv. 2012 Jun;5(3):372-80. doi: 10.1161/CIRCINTERVENTIONS.111.967257. Epub 2012 Jun 5.

35.

Very late stent thrombosis and late target lesion revascularization: no end in sight.

Faxon DP.

Circulation. 2012 Jan 31;125(4):562-4. doi: 10.1161/CIRCULATIONAHA.111.079731. Epub 2011 Dec 27. No abstract available.

36.

Transcatheter aortic valve implantation: coming of age.

Faxon DP.

Circulation. 2011 Oct 25;124(17):e439-40. doi: 10.1161/CIRCULATIONAHA.111.065243. Review. No abstract available.

37.

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary.

Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):522-34. doi: 10.1161/CIRCINTERVENTIONS.111.965186.

38.

Comparison of three age groups regarding safety and efficacy of drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Bainey KR, Selzer F, Cohen HA, Marroquin OC, Holper EM, Graham MM, Williams DO, Faxon DP.

Am J Cardiol. 2012 Jan 15;109(2):195-201. doi: 10.1016/j.amjcard.2011.08.028. Epub 2011 Oct 14.

39.

Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.

Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ.

Thromb Haemost. 2011 Oct;106(4):572-84. doi: 10.1160/TH11-04-0262. Epub 2011 Jul 25.

PMID:
21785808
40.

Revascularization of left main coronary artery disease.

Lee MS, Faxon DP.

Cardiol Rev. 2011 Jul-Aug;19(4):177-83. doi: 10.1097/CRD.0b013e318219244d. Review.

PMID:
21646871
41.

Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.

Faxon DP.

Catheter Cardiovasc Interv. 2012 Feb 1;79(2):181-97. doi: 10.1002/ccd.23163. Epub 2011 May 26. Review.

PMID:
21618679
42.

Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.

Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss M, Slater J, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group.

Circulation. 2011 Apr 12;123(14):1492-500. doi: 10.1161/CIRCULATIONAHA.110.978247. Epub 2011 Mar 28.

43.

Meta-analysis of multivessel coronary artery revascularization versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.

Bangalore S, Kumar S, Poddar KL, Ramasamy S, Rha SW, Faxon DP.

Am J Cardiol. 2011 May 1;107(9):1300-10. doi: 10.1016/j.amjcard.2010.12.039. Epub 2011 Feb 23.

PMID:
21349487
44.

Temporal changes in the outcomes of patients with diabetes mellitus undergoing percutaneous coronary intervention in the National Heart, Lung, and Blood Institute dynamic registry.

Holper EM, Abbott JD, Mulukutla S, Vlachos H, Selzer F, McGuire D, Faxon DP, Laskey W, Srinivas VS, Marroquin OC, Jacobs AK.

Am Heart J. 2011 Feb;161(2):397-403.e1. doi: 10.1016/j.ahj.2010.11.004.

PMID:
21315225
45.

Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry).

Parikh SV, Saya S, Divanji P, Banerjee S, Selzer F, Abbott JD, Naidu SS, Wilensky RL, Faxon DP, Jacobs AK, Holper EM.

Am J Cardiol. 2011 Apr 1;107(7):959-64. doi: 10.1016/j.amjcard.2010.11.019. Epub 2011 Jan 20.

46.

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators.

Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4.

PMID:
20817281
47.

Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry.

Bangalore S, Vlachos HA, Selzer F, Wilensky RL, Kip KE, Williams DO, Faxon DP.

Catheter Cardiovasc Interv. 2011 Jan 1;77(1):22-8. doi: 10.1002/ccd.22613.

48.

Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization?

Bangalore S, Faxon DP.

Curr Cardiol Rep. 2010 Jul;12(4):330-7. doi: 10.1007/s11886-010-0115-8. Review.

PMID:
20425159
49.

Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

Faxon DP.

Nat Rev Cardiol. 2010 Mar;7(3):124-5. doi: 10.1038/nrcardio.2009.247. No abstract available. Erratum in: Nat Rev Cardiol. 2010 May;7(5):242.

PMID:
20179718
50.

Examining treatment of ST-elevation myocardial infarction: the importance of early intervention.

Lamas GA, Escolar E, Faxon DP.

J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):6-16. doi: 10.1177/1074248409354600. Epub 2010 Jan 8. Review.

PMID:
20061507

Supplemental Content

Loading ...
Support Center